Here are five quick facts about the update:
• Integra LifeSciences now has a “Buy” consensus rating
• The average 12-month price target is $63.71.
• Argus raised the price total from $61 to $72 on March 25.
• Zacks reiterated “neutral” and set the price target at $63 last month.
• The company has a market cap of $2 billion and 50 day moving average of $59.
The company reported revenue at $252 million for the most recent quarter, up 14.2 percent year-over-year. The analysts predict the company will post $3.17 earnings per share in the current fiscal year.
More articles on orthopedic devices:
12 observations on implant materials for the next generation
16 spine devices receive FDA 510(k) clearance in March
Zimmer voluntarily recalls knee device
